Full Press Release Details
Accelerate Diagnostics Names Tom Brown
to Board of Directors
TUCSON, Ariz., March 15, 2017 (GLOBE NEWSWIRE) -- Accelerate
Diagnostics, Inc. today announced the election of Tom Brown to the company's board of directors. His appointment is effective
Brown's appointment adds over 30 years of medical diagnostics
expertise to the company's board of directors. Beginning his career with the Abbott Laboratories Diagnostics Division (ADD)
in 1974, Brown held numerous sales, marketing and general management positions of increasing responsibility. He served in positions
including Divisional Vice President of Sales within the United States, and Divisional Vice President and General Manager of the
Western Hemisphere, and by 1993 he was Corporate Vice President of Worldwide Diagnostic Commercial Operations. He was named Senior
Vice President before becoming President of the Diagnostic Division, the role he served until his retirement in 2002.
"Tom is a proven leader with a wealth of experience in
the diagnostics industry," said Chairman of the Board, John Patience. "His extensive background, particularly in launching
and commercializing new diagnostic solutions, will be increasingly valuable as the company launches the Accelerate Pheno
system and introduces additional novel solutions to the microbiology laboratory."
Tom Brown currently serves on the board of directors of Quidel
Corporation and Stericycle, Inc. and has previously served on the boards of Cepheid, Inc. and Ventana Medical Systems, Inc. He
received a Bachelor of Arts degree from the State University of New York at Buffalo.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. ("Accelerate Diagnostics"),
(Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic
resistance and healthcare-associated infections. The company's fully automated Accelerate Pheno system, and direct from
positive blood culture Accelerate PhenoTest BC kit, leverage a suite of technologies to eliminate the lengthy culture and
sample preparation steps required prior to testing. Using proprietary molecular identification methods and morphokinetic cellular
analysis (MCA), the solution aims to reduce the time that clinicians must wait for quantitative antimicrobial susceptibility results
necessary for optimal antibiotic selection, dosing, and infusion strategy, called minimum inhibitory concentrations, or MICs.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE
PHENO" and "ACCELERATE PHENOTEST" logos and marks are trademarks or registered trademarks of Accelerate Diagnostics,
For more information about the company, its products or technology,
Forward-Looking Statements
Certain of the statements made in this press release are
forward looking, such as those related to the contributions expected to be made by members of the company's board. Actual
results or developments may differ materially from those projected or implied in these forward-looking statements. Information
about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors"
in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2017,
and in any other reports that we file with the Securities and Exchange Commission from time to time. The company's forward-looking
statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company
undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100